IP Verse

Competitive analysis in Cancer Drugs industry

Latest patents granted in the Cancer Drugs industry

Patent:
EP3218406
Grant Date:
Oct 2, 2024
Title:
Binding Molecules Specific For Cd73 And Uses Thereof
Applicant:
MEDIMMUNE LIMITED
Patent:
EP3200591
Grant Date:
Sep 25, 2024
Title:
Central Memory T Cells For Adoptive T Cell Therapy
Applicant:
CITY OF HOPE
Patent:
EP2736487
Grant Date:
Aug 28, 2024
Title:
New (Trimethoxyphenylamino)Pyrimidinyl Formulations
Applicant:
RIGEL PHARMACEUTICALS, INC.
Patent:
EP2694072
Grant Date:
Aug 7, 2024
Title:
Combinations Of Akt Inhibitor Compounds And Abiraterone, And Methods Of Use
Applicant:
GENENTECH, INC.
Patent:
EP3206987
Grant Date:
Jul 24, 2024
Title:
Nanoparticles For Photodynamic Therapy, X-Ray Induced Photodynamic Therapy, Radiotherapy, Chemotherapy, Immunotherapy, And Any Combination Thereof
Applicant:
THE UNIVERSITY OF CHICAGO
Patent:
EP3102208
Grant Date:
Jul 17, 2024
Title:
Crystalline Polymorphs Of The Free Base Of 2-Hydroxy-6-((2-(1-Isopropyl-1H-Pyrazol-5-Yl)Pyridin-3-Yl)Methoxy)Benzaldehyde
Applicant:
GLOBAL BLOOD THERAPEUTICS, INC.
Patent:
EP3152234
Grant Date:
Jun 26, 2024
Title:
Antibody Which Is Directed Against Galectin-9 And Is An Inhibitor Of The Suppressor Activity Of Regulatory T Lymphocytes
Applicant:
CELLVAX
Patent:
EP3296395
Grant Date:
Jun 19, 2024
Title:
Multiple Antigen Binding Molecular Fusion, Pharmaceutical Composition, Method For Identifying Linear Epitope, And Method For Preparing Multiple Antigen Binding Molecular Fusion
Applicant:
CHUGAI SEIYAKU KABUSHIKI KAISHA
Patent:
EP2099480
Grant Date:
Jun 12, 2024
Title:
Microorganisms Of Fractions Thereof Capable Of Activating Cellular Immunity Against Carbohydrates
Applicant:
GLYCOTOPE GMBH
Patent:
EP3525781
Grant Date:
Apr 24, 2024
Title:
Composition Comprising Epa And Dha For An Enhanced Efficacy Of Anticancer Agents
Applicant:
FRESENIUS KABI DEUTSCHLAND GMBH

Top patents facing oppositions in Cancer Drugs industry

Patent:
EP3351246
Grant Date:
Sep 18, 2019
Title:
Rapamycin Derivative For The Treatment Of A Solid Tumor Associated With Deregulated Angiogenesis
Applicant:
NOVARTIS INTERNATIONAL PHARMACEUTICAL AG
Oppositions:
54
Patent:
EP2478907
Grant Date:
Apr 14, 2021
Title:
Methods And Compositions For Treating Cancer
Applicant:
COUGAR BIOTECHNOLOGY, INC.
Oppositions:
44
Patent:
EP2269603
Grant Date:
May 20, 2015
Title:
Treatment Of Solid Tumours With Rapamycin Derivatives
Applicant:
NOVARTIS AG
Oppositions:
36
Patent:
EP3342411
Grant Date:
Aug 21, 2019
Title:
Rapamycin Derivative For Treating Pancreas Cancer
Applicant:
NOVARTIS INTERNATIONAL PHARMACEUTICAL AG
Oppositions:
30
Patent:
EP2962690
Grant Date:
Jan 16, 2019
Title:
(+)-2-[1-(3-Ethoxy-4-Methoxyphenyl)-2-Methylsulfonylethyl]-4-Acetylaminoisoindoline-1,3-Dione: Methods Of Using And Compositions Thereof
Applicant:
AMGEN (EUROPE) GMBH
Oppositions:
30
Patent:
EP3616720
Grant Date:
Feb 17, 2021
Title:
Pharmaceutical Composition For Cancer Treatment
Applicant:
SHIONOGI & CO., LTD
Oppositions:
30
Patent:
EP2493466
Grant Date:
Mar 10, 2021
Title:
Novel Antitumoral Use Of Cabazitaxel
Applicant:
AVENTIS PHARMA S.A.
Oppositions:
26
Patent:
EP2780375
Grant Date:
Sep 11, 2019
Title:
Binding Molecules For Bcma And Cd3
Applicant:
AMGEN INC.
Oppositions:
24
Patent:
EP3391890
Grant Date:
Aug 25, 2021
Title:
Posaconazole Intravenous Solution Formulations Stabilized By Substituted Beta-Cyclodextrin
Applicant:
MERCK SHARP & DOHME LLC
Oppositions:
24
Patent:
EP3725778
Grant Date:
Aug 18, 2021
Title:
Formulations Of Enzalutamide
Applicant:
ASTELLAS PHARMA INC.
Oppositions:
22

Top companies filing oppositions in Cancer Drugs industry

Company:
STADA ARZNEIMITTEL AG
Total oppositions filed:
32
Company:
TEVA PHARMACEUTICAL INDUSTRIES LTD.
Total oppositions filed:
30
Company:
SANDOZ AG
Total oppositions filed:
26
Company:
GENERICS [UK] LIMITED
Total oppositions filed:
25
Company:
GENERICS (U.K.) LIMITED
Total oppositions filed:
24
Company:
TEVA PHARMACEUTICAL INDUSTRIES LTD
Total oppositions filed:
22
Company:
JAMES POOLE LIMITED
Total oppositions filed:
17
Company:
KONIG SZYNKA TILMANN VON RENESSE
Total oppositions filed:
16
Company:
STRAWMAN LIMITED
Total oppositions filed:
16
Company:
FRESENIUS KABI DEUTSCHLAND GMBH
Total oppositions filed:
14

Top companies facing oppositions in Cancer Drugs industry

Company:
NOVARTIS AG
Total facing oppositions:
114
Company:
NOVARTIS PHARMA AG
Total facing oppositions:
43
Company:
NOVARTIS INTERNATIONAL PHARMACEUTICAL AG
Total facing oppositions:
38
Company:
CELGENE CORPORATION
Total facing oppositions:
38
Company:
MERCK SHARP & DOHME CORP.
Total facing oppositions:
35
Company:
BOEHRINGER INGELHEIM INTERNATIONAL GMBH
Total facing oppositions:
27
Company:
BRISTOL-MYERS SQUIBB COMPANY
Total facing oppositions:
26
Company:
EISAI R&D MANAGEMENT CO., LTD.
Total facing oppositions:
26
Company:
MERCK SHARP & DOHME LLC
Total facing oppositions:
26
Company:
F. HOFFMANN-LA ROCHE AG
Total facing oppositions:
24

Need more information?

Feel free to send us a message here and we will get back to you